Related Experiment Video
Updated: Jun 22, 2025
04:57
Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
10.1K
Geriatric Nutritional Risk Index as Prognostic Marker for Elderly Patients With Small Cell Lung Cancer
Ryosuke Kinoshita1, Makoto Nakao1, Hiroko Kiyotoshi1
1Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan.
Cancer Diagnosis & Prognosis
|July 4, 2024
Summary
The Geriatric Nutritional Risk Index (GNRI) can predict outcomes for elderly patients with extensive-disease small-cell lung cancer (SCLC). A low GNRI score is linked to poorer survival rates in these patients receiving chemotherapy.
Area of Science:
- Oncology
- Geriatric Medicine
- Nutritional Science
Background:
- The Geriatric Nutritional Risk Index (GNRI) assesses nutritional status using serum albumin and ideal body weight.
- Pretreatment GNRI is a potential prognostic indicator for various cancers.
- Its clinical utility in elderly patients with extensive-disease small-cell lung cancer (ED-SCLC) remains underexplored.
Purpose of the Study:
- To investigate the prognostic value of pretreatment GNRI in elderly patients with ED-SCLC.
- To evaluate the association between GNRI levels and survival outcomes in this specific patient population.
Main Methods:
- Retrospective analysis of 53 elderly (≥71 years) patients with ED-SCLC.
- Patients received first-line platinum-doublet chemotherapy.
- Analysis correlated pretreatment GNRI levels with progression-free survival (PFS) and overall survival (OS).
Main Results:
- Patients with low GNRI (<92) showed significantly worse PFS (median 80 days) and OS (median 123 days) compared to those with high GNRI (≥92) (PFS: 133 days, OS: 274 days).
- Multivariate analysis confirmed low GNRI as an independent poor prognostic factor for both PFS (HR=0.396) and OS (HR=0.295).
Conclusions:
- GNRI may serve as a valuable predictive and prognostic marker for elderly patients with ED-SCLC undergoing platinum-doublet chemotherapy.
- This index could aid in risk stratification and treatment planning for this vulnerable patient group.
